Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:ITOSNYSE:MBXNYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.38-4.8%$1.38$1.01▼$3.45$407.93M1.051.68 million shs867,633 shsITOSiTeos Therapeutics$10.17+0.1%$8.98$4.80▼$18.13$389.63M1.49692,607 shs386,108 shsMBXMBX Biosciences$12.48+1.2%$11.43$4.81▼$27.50$416.96MN/A258,561 shs92,284 shsXTNTXtant Medical$0.69-0.2%$0.63$0.33▼$0.83$96.38M-0.14121,987 shs31,040 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca0.00%+5.34%-12.10%+18.97%-36.70%ITOSiTeos Therapeutics0.00%+2.21%-0.10%+88.68%-31.19%MBXMBX Biosciences0.00%+16.05%+5.19%+106.54%+1,247,499,900.00%XTNTXtant Medical0.00%+9.98%-2.19%+47.19%+9.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.0602 of 5 stars3.51.00.00.03.22.51.3ITOSiTeos Therapeutics3.1865 of 5 stars4.12.00.00.01.43.30.6MBXMBX Biosciences3.2526 of 5 stars3.50.00.00.03.33.30.6XTNTXtant Medical2.3448 of 5 stars3.53.00.00.02.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57231.26% UpsideITOSiTeos Therapeutics 2.14Hold$15.8655.92% UpsideMBXMBX Biosciences 3.00Buy$37.50200.60% UpsideXTNTXtant Medical 3.00Buy$1.50116.83% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, MBX, ERAS, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025ITOSiTeos TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025ITOSiTeos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2025ITOSiTeos TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.005/13/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$15.00 ➝ $8.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AITOSiTeos Therapeutics$35M11.12N/AN/A$16.16 per share0.63MBXMBX BiosciencesN/AN/AN/AN/AN/AN/AXTNTXtant Medical$117.27M0.82N/AN/A$0.31 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)MBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AXTNTXtant Medical-$16.45M-$0.13N/A∞N/A-9.81%-27.01%-12.49%8/14/2025 (Estimated)Latest XTNT, MBX, ERAS, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35ITOSiTeos TherapeuticsN/A14.1314.13MBXMBX BiosciencesN/AN/AN/AXTNTXtant Medical0.512.341.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%ITOSiTeos Therapeutics97.16%MBXMBX BiosciencesN/AXTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%ITOSiTeos Therapeutics12.50%MBXMBX Biosciences52.19%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableMBXMBX Biosciences3633.42 millionN/AN/AXTNTXtant Medical120139.32 million125.81 millionNot OptionableXTNT, MBX, ERAS, and ITOS HeadlinesRecent News About These CompaniesXtant Medical (NYSEAMERICAN:XTNT) Stock Crosses Above 200-Day Moving Average - Time to Sell?July 2, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above Two Hundred Day Moving Average - Here's What HappenedJune 24, 2025 | marketbeat.comXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest UpdateJune 15, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?June 7, 2025 | marketbeat.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comXtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new productsMay 13, 2025 | msn.comXtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comXtant Medical Reports First Quarter 2025 Financial ResultsMay 12, 2025 | prnewswire.com6XTNT : A Glimpse of Xtant Medical Hldgs&#...May 9, 2025 | benzinga.comXtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025May 6, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 6.27%April 29, 2025 | aaii.comAXtant Medical Launches Trivium™ Advanced Bone Graft for Superior PerformanceApril 23, 2025 | prnewswire.comXtant Medical secures investor support, projects Q1 revenue growthApril 18, 2025 | uk.investing.comXtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65MApril 17, 2025 | markets.businessinsider.comXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%April 16, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 14.76%April 10, 2025 | aaii.comAWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 12.52%March 22, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, MBX, ERAS, and ITOS Company DescriptionsErasca NASDAQ:ERAS$1.38 -0.07 (-4.83%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 07/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.iTeos Therapeutics NASDAQ:ITOS$10.17 +0.01 (+0.10%) As of 07/3/2025 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.MBX Biosciences NYSE:MBX$12.48 +0.15 (+1.18%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Xtant Medical NYSEAMERICAN:XTNT$0.69 0.00 (-0.17%) As of 07/3/2025 05:00 PM EasternXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
